Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story
Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.
How this was made
The 30-second read
Why it matters
The earnings beat and strategic partnership together drive a near‑10% price surge, suggesting short‑term buying interest.
Market read
The news combines earnings momentum with a high‑profile AI partnership, making TWST a notable short‑term trade idea in the biotech/AI crossover space.
What to watch
Potential execution risk of the Lilly partnership and macro‑risk to growth‑oriented biotech stocks.
Background
Twist Bioscience, a synthetic DNA manufacturer, posted its Q3 FY26 results and announced a new data‑services contract with Eli Lilly's AI platform.
Ticker impact
Twist Bioscience reported Q3 FY26 revenue of $118.4M, raised full-year guidance to $456‑$457M and announced a Lilly AI data‑services agreement, prompting a 9.94% stock jump.
Expect continued upward pressure over the next few trading days, with potential breakout if guidance holds.
Strong top‑line growth, margin expansion, and a high‑profile AI collaboration provide concrete catalysts for price appreciation.
Market effects
Reinforces AI‑driven biotech tools theme, may lift peers in synthetic DNA and biotech services.
U.S. biotech sector gains momentum; limited direct impact outside North America.
Highlights growing pharma‑AI collaborations, relevant for global biotech investors.
Counterpoint
High valuation and ongoing losses could limit upside; the deal may be smaller than implied.
Key entities
- companyTwist Bioscience
Synthetic DNA and biotech tools provider (NASDAQ: TWST).
- companyEli Lilly
Pharmaceutical giant partnering with Twist for AI‑driven antibody data.
